SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 145 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,227,823 | -33.6% | 635,525 | -4.4% | 0.00% | -33.3% |
| Q2 2023 | $13,907,294 | +10.7% | 664,467 | +11.7% | 0.00% | +50.0% |
| Q1 2023 | $12,564,794 | -10.1% | 594,924 | +8.3% | 0.00% | -33.3% |
| Q4 2022 | $13,974,366 | +15.4% | 549,091 | +9.0% | 0.00% | 0.0% |
| Q3 2022 | $12,111,000 | +29.0% | 503,962 | +3.3% | 0.00% | +50.0% |
| Q2 2022 | $9,387,000 | +11.1% | 487,913 | +0.3% | 0.00% | +100.0% |
| Q1 2022 | $8,450,000 | -14.9% | 486,228 | +7.2% | 0.00% | -50.0% |
| Q4 2021 | $9,931,000 | +13.4% | 453,676 | -1.0% | 0.00% | 0.0% |
| Q3 2021 | $8,756,000 | +11.1% | 458,176 | -0.2% | 0.00% | +100.0% |
| Q2 2021 | $7,879,000 | -3.6% | 458,937 | +25.6% | 0.00% | -50.0% |
| Q1 2021 | $8,172,000 | +5.6% | 365,486 | +5.1% | 0.00% | 0.0% |
| Q4 2020 | $7,735,000 | +53.7% | 347,774 | +2.0% | 0.00% | +100.0% |
| Q3 2020 | $5,031,000 | -4.3% | 340,910 | -3.9% | 0.00% | 0.0% |
| Q2 2020 | $5,257,000 | +73.8% | 354,749 | +28.7% | 0.00% | 0.0% |
| Q1 2020 | $3,024,000 | +42.6% | 275,615 | +14.1% | 0.00% | – |
| Q4 2019 | $2,121,000 | +16.5% | 241,549 | -0.9% | 0.00% | – |
| Q3 2019 | $1,820,000 | +3.9% | 243,713 | +29.6% | 0.00% | – |
| Q2 2019 | $1,751,000 | +88.9% | 188,082 | +6.5% | 0.00% | – |
| Q1 2019 | $927,000 | +18.7% | 176,612 | +0.6% | 0.00% | – |
| Q4 2018 | $781,000 | -44.1% | 175,492 | +1.6% | 0.00% | – |
| Q3 2018 | $1,396,000 | +13.7% | 172,802 | -1.2% | 0.00% | – |
| Q2 2018 | $1,228,000 | -40.0% | 174,877 | +21.7% | 0.00% | -100.0% |
| Q1 2018 | $2,046,000 | +51.7% | 143,731 | -6.7% | 0.00% | – |
| Q4 2017 | $1,349,000 | -9.5% | 154,001 | +21.0% | 0.00% | – |
| Q3 2017 | $1,490,000 | -18.1% | 127,277 | -2.2% | 0.00% | -100.0% |
| Q2 2017 | $1,819,000 | +98.4% | 130,196 | +94.7% | 0.00% | – |
| Q1 2017 | $917,000 | +112.8% | 66,860 | +11.2% | 0.00% | – |
| Q4 2016 | $431,000 | -46.3% | 60,102 | +13.5% | 0.00% | – |
| Q3 2016 | $802,000 | +62.0% | 52,951 | +5.4% | 0.00% | – |
| Q2 2016 | $495,000 | – | 50,215 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |